pharmaceut question next week
publish separ compani report includ revisit thesi question
corpor manag head next week west coast meet along view
also provid result latest investor survey exhibit link larg cap pharma
initi report see separ note morn detail feedback/push-back launch
link question manag team host meet next week
thesi question rais price target hurdl remain
thesi question sunosi ramp strategi key
address five recur question get look
thesi question expect exparel momentum
question still execut stori need inflect year
teva thesi question teva growth/margin concern keep us cautiou
larg cap pharma pharmaceut expand larg cap pharma
cautiou margin outlook dividend larg initi sp price target
solid growth stori also healthi appreci initi sp price target
 inflect innov high growth base initi op target
stand top idea current investor sentiment per survey
ran quick investor survey last week gaug earli year sentiment ahead next week meet
specif outlook follow sept survey look expect year-
end sever notabl within specialti pharma remain stock seen
upsid close went second last clear second ii teva remain
stock seen downsid iron follow perhap reflect long/short
debat iii term sector biotech expect perform best take place
med-tech interestingli iv large-cap pharma follow specialti pharma expect perform
worst togeth garner respons also poll direct healthcar stock
perform next week skew posit exhibit final open end question ask
top theme next week skew heavili toward biotech follow pricing/regul term
top idea
large-cap pharma op price target robust growth stori revenu
ep compound-annual-growth-rate loe year away ii manag upjohn-rel
ep step-down help drive sentiment neg like set-up smaller base
gener pharma op price target stock may rang bound mid-year
upjohn deal close see sharp back-half inflect come overhang lift newco valuat
re-rat see newco ebitda base trough dividend new corpor govern
leverag move lower
specialti pharma op price target see continu growth lead product exparel
multitud tailwind competit concern set address continu see
strateg valu asset
meet much coverag next week look
expect pre-announc detail along xyrem volum guidanc street
impli achiev xyrem revenu growth goal past year also separ
sell-sid event expect provid detail innov strategi around core csca
busi expect pre-announc thur host investor event mon
follow dinner link teva confirm guidanc updat
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
pharmaceut question next week
pharmaceut sentiment survey add set-up color
survey investor look color around sector stock sentiment
focu posit surprisingli sentiment within specialti pharmaceut
remain challeng gener consist investor convers perhap
surpris fact large-cap pharma sentiment wors per survey
similar prior survey respons weight toward long-short investor nearli
respond detail result exhibit along
comparison septemb survey relev
exhibit pleas describ invest style
investor continu point upsid second place
swap pacira rais price target earlier week continu
like set-up get upjohn deal close mid-year
exhibit specialti pharmaceut stock upsid septemb versu
pharmaceut question next week
note sep ask upsid remaind wherea jan ask upsid
littl movement among stock investor see downsid teva
endo face potenti signific opioid-rel liabil keep top
three stay steadi debat around xyrem life cycl strategi like keep
exhibit specialti pharmaceut stock downsid septemb versu
note sep ask downsid remaind wherea jan ask downsid
sector perspect expect perform best like reflect
enthusiasm around potenti one top theme med-tech took top
spot prior survey like reflect safeti trade year-end
exhibit healthcar subsector expect perform best septemb versu
pharmaceut question next week
note sep ask perform remaind wherea jan ask perform
specialti pharma final displac large-cap pharma least favor sector
initi big pharma week said suspect less improv
specialti pharma sentiment rather elect year concern large-cap pharma
expos
exhibit healthcar subsector expect perform worst septemb versu
note sep ask perform remaind wherea jan ask perform
nearli half investor expect flat healthcar market head next week jp morgan
healthcar confer among remain respond strong bia toward
healthcar market respond
pharmaceut question next week
exhibit expect healthcar stock trade remain neutral
jp morgan healthcar confer end januari
pharmaceut question next week
